Clinical trial
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
NCT00471133 · Ichor Medical Systems Incorporated, Industry · Completed
Key facts
| NCT number | NCT00471133 |
|---|---|
| Title | Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation |
| Official title | A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma |
| Lead sponsor | Ichor Medical Systems Incorporated, Industry |
| Collaborators | Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin), Intraocular Melanoma |
| Intervention type | Biological, Device |
| Interventions | Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation |
| Enrollment | 24 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | May 9, 2007 |
| Last update posted | Jun 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: